Brief: Dare Bioscience Announces Return Of Rights To Ovaprene Phase 3 Program Ongoing Positive Interim Data

Dare Bioscience

01/12/2025 13:07

Dec 1 (Reuters) - Dare Bioscience Inc DARE.O:

DARÉ BIOSCIENCE ANNOUNCES RETURN OF RIGHTS TO OVAPRENE®; PHASE 3 PROGRAM ONGOING; POSITIVE INTERIM DATA AND GRANT FUNDING POSITION ASSET FOR VALUE-MAXIMIZATION

DARE BIOSCIENCE INC - TERMINATION EFFECTIVE FEBRUARY 2026, DARÉ GAINS FULL CONTROL OF OVAPRENE

Source text: ID:nGNXbsjQfc

Further company coverage: DARE.O

 ((Reuters.Briefs@thomsonreuters.com;))